🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tangshan
Clinical trial register · China

Clinical Trials in Tangshan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Peking Union Medical College Hospital3 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.2 Nanjing RegeneCore Biotech Co., Ltd.2 Jiangsu BioJeTay Biotechnology Co., Ltd.2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tangshan

36 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
NCT07822646Ovarian Cancer
Chinese PLA General Hospital
Phase 3
120
Beijing, Tangshan, Taiyuan
2026-10-12
Not yet open
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
NCT07466251Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
1,212
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2026-09-01
Not yet open
Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature
NCT07815626Idiopathic Short Stature (ISS)
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase 3
240
Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing
2026-09
Recruiting
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
NCT07710248Primary Immune Thrombocytopenia
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
60
Fuzhou, Guangzhou, Liuzhou, Yulin, Baoding, Chengde, Tangshan, Harbin
2026-06-11
Not yet open
Differences in Pelvic Floor Motion Level Among Chinese Women and Construction of an Assessment System
NCT07608146Stress Urinary Incontinence (SUI)
Peking Union Medical College Hospital
Observational
2,000
Hefei, Beijing, Linxia, Qinzhou, Guiyang, Zunyi, Tangshan, Mudanjiang
2026-05-30
Active, closed
Effects of Digital Health Interventions on the Physical and Mental Health of Middle School Students
NCT06547567Pediatric Obesity
Peking University
Not applicable
800
Tangshan
2026-05-12
Not yet open
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT07465120Moderate to Severe Atopic Dermatitis
Dermavon Holdings Limited
Phase 2
160
Beijing, Fuzhou, Guangzhou, Shenzhen, Haikou, Shijiazhuang, Tangshan, Zhengzhou
2026-03-20
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487Moderate to Severe Asthma
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
195
Anqing, Suzhou, Beijing, Chongqing, Lanzhou, Shijiazhuang, Tangshan, Xingtai
2026-03-10
Recruiting
Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lung Resection
NCT07018375Chronic Postsurgical Pain
Tianjin Medical University General Hospital
Phase 4
320
Baoding, Tangshan, Tianjin
2026-01-06
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
NCT07179679Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Active, closed
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
NCT07263776Acute Ischemic Stroke
Capital Medical University
Phase 3
692
Suzhou, Zhangzhou, Qinzhou, Langfang, Qinhuangdao, Tangshan, Harbin, Anyang
2025-12-05
Recruiting
A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease
NCT07640893Von Willebrand Disease (VWD)
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
24
Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin
2025-11-26
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Recruiting
Efficacy of Kinesio Taping Versus Compression Therapy on Breast Lymphedema Induced by Radiotherapy After Breast-Conserving Surgery
NCT07767305Breast Cancer, Breast Lymphedema
Tangshan People's Hospital
Not applicable
99
Tangshan
2025-10-01
Recruiting
Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2
NCT07097818Type 1 Diabetes
Second Xiangya Hospital of Central South University
Not applicable
400
Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang
2025-08-18
Recruiting
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
NCT06929299Primary Immune Thrombocytopenia (ITP)
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xi’an, Tianjin
2025-05-12
Recruiting
Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes
NCT06861062Diabetes Mellitus, Type 2
Huazhong University of Science and Technology
Not applicable
2,500
Nanning, Tangshan, Shiyan, Wuhan, Chengdu
2025-04-08
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
NCT06825494Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
NCT06833983Hemophilia A
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Active, closed
Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
NCT06922045Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
NCT06756451Hematologic Malignancies
Nanjing RegeneCore Biotech Co., Ltd.
Phase 1
71
Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou
2025-03-25
Not yet open
Inflammatory and Metabolic Prognostic Assessment in Critically Ill Neurological Patients
NCT06849011Stroke Acute, Encephalitis, Non-traumatic Brain Injury
Yan Zhang
Observational
1,185
Beijing, Lanzhou, Guiyang, Zunyi, Tangshan, Shijiazhuang, Hohhot, Suzhou
2025-03-01
Active, closed
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
NCT06738485Congenital Hemophilia A
CSL Behring
Phase 3
60
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Tangshan, Tianjin
2025-01-09
Recruiting
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
NCT07017725Chronic Immune Thrombocytopenia
CASI pharmaceuticals, Inc.
Phase 1/2
75
Tangshan, Zhengzhou, Nanchang, Jinan, Tianjin, Kunming
2025-01-03
Not yet open
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
NCT06469879Small Cell Lung Cancer Limited Stage
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
358
Hefei, Lanzhou, Nanjing, Tangshan, Harbin, Anyang, Xiangyang, Changsha
2024-09
Recruiting
The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction
NCT06374667Stroke, Acute Ischemic, Blood-Brain Barrier
yilong Wang
Not applicable
134
Wuhu, Beijing, Tangshan, Xi'an, Tianjin
2024-04-22
Recruiting
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
NCT06122831Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
92
Guangzhou, Nanning, Cangzhou, Chengde, Tangshan, Xingtai, Harbin, Zhengzhou
2023-12-12
Active, closed
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
NCT05987358Biliary Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
165
Beijing, Lanzhou, Tangshan, Shanghai, Tianjin
2023-09-21
Recruiting
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
NCT05908695Alzheimer's Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
1,312
Huainan, Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Shijiazhuang, Tangshan
2023-08-31
Active, closed
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
NCT06009861Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Fuzhou, Lanzhou, Guangzhou, Meizhou, Haikou, Chengde, Tangshan, Harbin
2022-10-24
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Recruiting
Clinical Indicators and Brain Image Data: a Study Based on Kailuan Cohort
NCT05453877Brain Diseases, Hypertension
Beijing Friendship Hospital
Observational
1,000
Beijing, Tangshan
2022-08-01
Active, closed
Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug
NCT05203679Hemophilia B
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
NCT04948749ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke
Beijing Tiantan Hospital
Not applicable
358
Beijing, Cangzhou, Tangshan, Xingtai, Wuhan, Baotou, Hohhot, Tongliao
2021-07-02
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/tangshan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Tangshan.

How many clinical trials are recruiting in Tangshan?

22 of the 36 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tangshan), 36 studies
PhaseStudiesRecruitingShare
Phase 311430.6%
Not applicable6516.7%
Phase 25313.9%
Phase 1/24411.1%
Phase 44311.1%
Observational318.3%
Phase 1225.6%
Phase 2/3102.8%

Most active sponsors

Lead sponsors with the most studies (Tangshan)
Lead sponsorStudiesRecruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.31
Peking Union Medical College Hospital31
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.22
Jiangsu BioJeTay Biotechnology Co., Ltd.21
Nanjing RegeneCore Biotech Co., Ltd.22
Beijing Friendship Hospital11
Beijing Tiantan Hospital11
Capital Medical University10
CASI pharmaceuticals, Inc.11
Chinese PLA General Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.